Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lesinurad (RDEA594) 是URAT1和OAT 抑制剂。Lesinurad 用作肾转运蛋白OAT1 和OAT3 的底物,Km 分别为 0.85 和 2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 313 | 现货 | ||
10 mg | ¥ 452 | 现货 | ||
25 mg | ¥ 715 | 现货 | ||
50 mg | ¥ 1,190 | 现货 | ||
100 mg | ¥ 1,890 | 现货 | ||
200 mg | ¥ 2,850 | 现货 | ||
500 mg | ¥ 4,630 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 387 | 现货 |
产品描述 | Lesinurad (RDEA594) is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout. Lesinurad has had a limited clinical use but has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury. |
靶点活性 | OAT3:2 µM (Km), OAT1:0.85 µM (Km) |
体外活性 | Lesinurad inhibits the uric acid transport activity of human URAT1 (hURAT1) at a 20-fold higher potency compared to rat URAT1 (rURAT1), with IC50's of 3.36 and 74.84 μM, respectively. Lesinurad inhibits hURAT1 through an interaction that involves a critical residue, Phe365[1]. |
体内活性 | Lesinurad (RDEA594) exhibits better pharmacokinetics than its pro-drug RDEA806. The 100 mg dose of Lesinurad exhibits a pharmacological effect in the range of that produced by 300 mg to 800 mg single doses of RDEA806[2]. |
细胞实验 | Lesinurad is solubilized in DMSO and stored, and then diluted with appropriate media before use[1]. Validated oocytes, HEK293, MDCK-II, Caco-2 or MDCK-MDR1 cell systems are used to study the interaction of Lesinurad with membrane transporters localized to the kidney (OAT1, OAT3, OCT2, MATE1, and MATE2K) or liver (P-gp, BCRP, OATP1B1, OATP1B3, and OCT1). Xenopus laevis oocytes are injected with OAT1 or OAT3 cRNA or control (water) while HEK293 cells are stably transfected with MATE1, MATE2K, or vector and MDCK-II cells with hOATP1B1, hOATP1B3, hOCT1, hOCT2, or vector. The MDCKII cell line is stably transfected with the human MDR1 gene to create a P-gp cell line. The interaction of Lesinurad with BCRP relied on the endogenous expression in Caco-2 cells. All cells are cultured with growth medium according to standard methodology. In order to determine whether Lesinurad is a substrate for a transporter, cells are incubated with [14C]-labeled Lesinurad at various concentrations and the amount of Lesinurad taken up by the cells determined by subtracting the uptake in vector cells from that in the transfected cells. The uptake of a [3H]-labeled known substrate of the transporter served as the positive control. Inhibition of a transporter by Lesinurad is determined by incubating cells with a fixed concentration of [3H]-labeled known substrate and various concentrations of unlabeled Lesinurad. Inhibition by a known inhibitor of each transporter served as the positive control. Cells are incubated for the appropriate amount of time. All reactions are terminated by the addition of ice-cold medium. The cells are then rinsed with medium and lysed[1]. |
别名 | RDEA594, 雷西那德, 来司诺雷 |
分子量 | 404.28 |
分子式 | C17H14BrN3O2S |
CAS No. | 878672-00-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 74 mg/mL (183 mM)
Ethanol: 50 mg/mL (123.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.4735 mL | 12.3677 mL | 24.7353 mL | 61.8383 mL |
5 mM | 0.4947 mL | 2.4735 mL | 4.9471 mL | 12.3677 mL | |
10 mM | 0.2474 mL | 1.2368 mL | 2.4735 mL | 6.1838 mL | |
20 mM | 0.1237 mL | 0.6184 mL | 1.2368 mL | 3.0919 mL | |
50 mM | 0.0495 mL | 0.2474 mL | 0.4947 mL | 1.2368 mL | |
100 mM | 0.0247 mL | 0.1237 mL | 0.2474 mL | 0.6184 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lesinurad 878672-00-5 Membrane transporter/Ion channel OAT RDEA594 SLC22A12 Inhibitor inhibit 雷西那德 来司诺雷 URAT1 Urate transporter 1 RDEA 594 RDEA-594 inhibitor